At the start of the study, the patients’ viral loads were around 88,100 copies/ ml, but after 48 weeks, 78% of the patients taking Reyataz (343 out of 440) had viral loads below 50 copies/ ml, compared with 76% of those taking lopinavir (338 out of 443).